Debate

DOI: 10.4244/EIJ-E-24-00009

Antiplatelet monotherapy after DAPT: is clopidogrel the new standard? Pros and cons

Hyo-Soo Kim1, MD; Jeehoon Kang1, MD; Giulio Stefanini2,3, MD, MSc, PhD; Raffaele De Caterina4,5, MD, PhD

Introduction

Antiplatelet monotherapy is the standard of care for secondary prevention after an initial course of dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome or undergoing percutaneous coronary intervention (PCI). Aspirin has long been the drug of choice for this purpose and is still recommended under Class I by guidelines. However, randomised trials and meta-analyses suggested a potential benefit with clopidogrel, a P2Y12 receptor inhibitor. As such, a Class IIb recommendation supporting the use of clopidogrel for long-term secondary prevention has been yielded by the latest guidelines. Nevertheless, limitations regarding enrolled populations and study design should be considered when interpreting such findings. Whether current evidence is enough to advocate the routine use of clopidogrel instead of aspirin for long-term secondary prevention is a matter for debate.

Pros

Hyo-Soo Kim, MD; Jeehoon Kang, MD

Medical treatment including antithrombotic therapy after PCI is essential in preventing recurrence. After the initial period of intensive antithrombotic therapy (usually DAPT), antiplatelet monotherapy is used as secondary prevention.

Guidelines “still” state that aspirin should be the first-line antiplatelet agent for secondary prevention

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 12
Jun 17, 2024
Volume 20 Number 12
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV15I12A192 Dec 20, 2019
GLOBAL LEADERS: looking now at the bigger picture
Guedeney P and Montalescot G
free

Perspective

10.4244/EIJ-E-23-00001 Apr 3, 2023
Aspirin should be stopped at day 0 after PCI: pros and cons
Gurbel P et al
free

Editorial

10.4244/EIJ-E-24-00027 May 20, 2024
Can DAPT be discontinued at one month after PCI in high bleeding risk patients presenting with ACS?
Hong M and Lee Y
free

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free

10.4244/EIJV11I13A281 Apr 20, 2016
DAPT: a historical accident in the pharmacological treatment of post-percutaneous coronary intervention
Suwannasom P and Serruys PW
free
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
38.95

State-of-the-Art

10.4244/EIJ-D-23-00912 Oct 7, 2024
Optical coherence tomography to guide percutaneous coronary intervention
Almajid F et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved